Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL6547534 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1125864 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL302681 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL419844 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL3097543 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1429909 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL302680 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| D-Proline SCHEMBL18493080 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1675389 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1895918 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079064-A1 | Preparation of Type I Collagen-Like Fiber and Method for Regulating and Controlling the D-periodic of Fiber Thereof | RUTGERS UNIVERSITY | 2021-03-18 | — | — | US | claimed |
| US-10335448-B2 | Compositions and methods for inhibiting fibrosis | THE UAB RESEARCH FOUNDATION (US) | 2019-07-02 | — | — | US | claimed |
| US-20170333517-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FIBROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-23 | — | — | US | claimed |
| WO-2016077365-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FIBROSIS | THE UAB RESEARCH FOUNDATION (US) | 2016-05-19 | — | — | WO | claimed |
| WO-2015164289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | claimed |
| US-20120065123-A1 | Synthetic Antibodies | NATIONAL INSTITUTES OF HEALTH | 2012-03-15 | — | — | US | claimed |
| US-20120021967-A1 | SYNTHETIC ANTIBODIES | Arizona Board of Regents, A Body Corporate of the State Of Arizona Acting for and Behalf of Arizona (US) | 2012-01-26 | — | — | US | claimed |
| WO-2010111299-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2010-09-30 | — | — | WO | claimed |
| WO-2009140039-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-11-19 | — | — | WO | claimed |
| EP-1560590-B1 | SYNTHETIC COMPLEMENTARY PEPTIDES AND OPHTHALMOLOGIC USES THEREOF | FORNIX BIOSCIENCES N V (NL) | 2008-10-22 | — | — | EP | claimed |
| US-20060216305-A1 | Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION, THE | 2006-09-28 | — | — | US | claimed |
| EP-1560590-A2 | SYNTHETIC COMPLEMENTARY PEPTIDES AND OPHTHALMOLOGIC USES THEREOF | Fornix Biosciences N.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| EP-1560590-A4 | SYNTHETIC COMPLEMENTARY PEPTIDES AND OPHTHALMOLOGIC USES THEREOF | FORNIX BIOSCIENCES N V (NL) | 2005-08-10 | — | — | EP | claimed |
| US-6762166-B2 | COMPLEMENTARY PEPTIDES FOR THE PROLINE-GLYCINE-PROLINE SEQUENCE AS ANTAGONISTS OF POLYMORPHONUCLEAR LEUKOCYTE CHEMOATTRACTANTS; TREATING ALKALI-INJURIED EYES | FORNIX BIOSCIENCES N.V. (NL) | 2004-07-13 | — | — | US | claimed |
| US-20020107202-A1 | Synthetic complementary peptides and ophthalmologic uses thereof | HADDOX JEFFREY LYNN (US) | 2002-08-08 | — | — | US | claimed |
| US-6310041-B1 | FOR TREATMENT OF EYE DISEASE SELECTED FROM ALKALI-INJURED EYE, CHEMICALLY INJURED EYE AND INFLAMMATORY DISEASE OF THE EYE | FORNIX BIOSCIENCES N.V. (NL) | 2001-10-30 | — | — | US | claimed |
| WO-2000053621-A2 | SYNTHETIC COMPLEMENTARY PEPTIDES AND OPHTHALMOLOGIC USES THEREOF | HADDOX JEFFREY LYNN (US) | 2000-09-14 | — | — | WO | claimed |
| US-11976052-B2 | Leukotriene synthesis inhibitors | NAEGIS PHARMACEUTICALS INC. (CA) | 2024-05-07 | — | — | US | disclosed |
| EP-0670727-A1 | COMPOUNDS THAT INHIBIT T CELL PROLIFERATION AND METHODS USING THE SAME | THOMAS JEFFERSON UNIVERSITY (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994011014-A1 | COMPOUNDS THAT INHIBIT T CELL PROLIFERATION AND METHODS USING THE SAME | THOMAS JEFFERSON UNIVERSITY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079064-A1 | Preparation of Type I Collagen-Like Fiber and Method for Regulating and Controlling the D-periodic of Fiber Thereof | COL14A1, COL1A1, COL2A1 | NOS2 3438/4885NOS3 3326/4885NOS1 2717/4885 |
| US-11976052-B2 | Leukotriene synthesis inhibitors | LTC4S, LTB4R2, LTA4H | NOS2 726/4885NOS3 1018/4885NOS1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.